Open AccessSaphenous Vein Graft Stenting and Major Adverse Cardiac Events
Author(s) -
Alanna Coolong,
Donald S. Baim,
Richard E. Kuntz,
A. James O’Malley,
Sachin Marulkar,
Donald E. Cutlip,
Jeffrey J. Popma,
Laura Mauri
Publication year - 2008
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.106.651232
Subject(s) - mace , medicine , percutaneous coronary intervention , cardiology , myocardial infarction
Treatment of saphenous vein graft (SVG) stenosis with percutaneous coronary intervention has a 15% to 20% incidence of major adverse cardiac events (MACE) within 30 days. Although MACE rates are reduced significantly by the use of embolic protection devices (EPDs), neither the level of baseline risk nor the benefit provided by EPDs has been well characterized.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom